- Home
- CDXS vs VNDA Comparison
CDXS vs VNDA Comparison
Compare CDXS & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDXS
- VNDA
- Stock Information
- Founded
- CDXS 2002
- VNDA 2002
- Country
- CDXS United States
- VNDA United States
- Employees
- CDXS N/A
- VNDA N/A
- Industry
- CDXS Major Chemicals
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- CDXS Industrials
- VNDA Health Care
- Exchange
- CDXS Nasdaq
- VNDA Nasdaq
- Market Cap
- CDXS 254.3M
- VNDA 249.4M
- IPO Year
- CDXS 2010
- VNDA 2006
- Fundamental
- Price
- CDXS $2.44
- VNDA $4.38
- Analyst Decision
- CDXS Buy
- VNDA Strong Buy
- Analyst Count
- CDXS 2
- VNDA 2
- Target Price
- CDXS $11.00
- VNDA $16.50
- AVG Volume (30 Days)
- CDXS 1.1M
- VNDA 388.7K
- Earning Date
- CDXS 10-30-2025
- VNDA 11-05-2025
- Dividend Yield
- CDXS N/A
- VNDA N/A
- EPS Growth
- CDXS N/A
- VNDA N/A
- EPS
- CDXS N/A
- VNDA N/A
- Revenue
- CDXS $57,164,000.00
- VNDA $203,467,000.00
- Revenue This Year
- CDXS $12.88
- VNDA $15.45
- Revenue Next Year
- CDXS $21.64
- VNDA $37.82
- P/E Ratio
- CDXS N/A
- VNDA N/A
- Revenue Growth
- CDXS N/A
- VNDA 11.78
- 52 Week Low
- CDXS $1.90
- VNDA $3.81
- 52 Week High
- CDXS $6.08
- VNDA $5.55
- Technical
- Relative Strength Index (RSI)
- CDXS 37.30
- VNDA 41.13
- Support Level
- CDXS $2.37
- VNDA $4.54
- Resistance Level
- CDXS $2.54
- VNDA $4.64
- Average True Range (ATR)
- CDXS 0.12
- VNDA 0.15
- MACD
- CDXS -0.01
- VNDA -0.02
- Stochastic Oscillator
- CDXS 30.00
- VNDA 0.00
About CDXS Codexis Inc.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.